Sashmal Swati, Mukherjee Swarupanada, Ray Subhabrata, Thakur Ram Sharnagat, Ghosh Lakshmi K, Gupta Bijan K
Ranbaxy Research Lab, Guargaon, India.
Pak J Pharm Sci. 2007 Apr;20(2):157-62.
The objective of the study was to design and evaluate NSAID loaded Nanoparticles drug delivery system, where Flurbiprofen (model drug) Nanoparticles with suitable size range are envisaged to concentrate at inflammation sites due to increase fragility of blood vessels at those sites and increased aggregation and prostaglandin synthesis. Materials used were surfactant (pluronic F 68) and polymer (poly lactic co glycolic acid; PLGA). The flurbiprofen loaded nanoparticles were prepared by solvent diffusion nano-precipitation method. Experiment was carried out following 3(2) factorial designs, where drug-polymer ratio was varied to optimize the formulation. From I.R studies no drug-polymer interaction was found. Particles size analysis was done using Malvern Mastersizer. Two parameters, namely, drug-polymer ratio and solvent-nonsolvent ratio were chosen for optimization following the factorial design. Amount of drug loading and surfactant were kept constant, and only polymer load was varied. The in-vitro drug release profile from nanoparticles was found to follow Higuchi square root kinetics implying a diffusion dependent release as is expected of an insoluble, non-swellable nature of PLGA. It indicated that nanoparticles formed were matrix in nature, in which flurbiprofen dispersed uniformly. Suitable polynomial models were generated and statistically validated using ANOVA for the different responses, namely drug release (maximization) and particle size (minimization). Those models were solved numerically and simultaneously to optimize the required formulation. Optimized formulation were found to have a polymer-drug ratio of 18.89:1 and manufactured at a nonsolvent-solvent ratio of 4:1 to maximized release after 8 hrs and minimized particle size. The methodology avoids the use of organic solvent and thus provides a safe, reproducible and fast method of production of nanoparticles. The study collaborates on the feasibility and suitability of aqueous polymeric drug delivery system, employing statistical design to develop a clinically useful Nanoparticle system with targeting potential.
本研究的目的是设计并评估载有非甾体抗炎药(NSAID)的纳米颗粒药物递送系统,设想将具有合适尺寸范围的氟比洛芬(模型药物)纳米颗粒聚集在炎症部位,这是由于这些部位血管的脆弱性增加以及聚集和前列腺素合成增加。所用材料为表面活性剂(泊洛沙姆F 68)和聚合物(聚乳酸 - 乙醇酸共聚物;PLGA)。通过溶剂扩散纳米沉淀法制备载有氟比洛芬的纳米颗粒。实验按照3(2)析因设计进行,其中改变药物 - 聚合物比例以优化制剂。红外光谱研究未发现药物 - 聚合物相互作用。使用马尔文粒度分析仪进行粒度分析。按照析因设计选择药物 - 聚合物比例和溶剂 - 非溶剂比例这两个参数进行优化。药物负载量和表面活性剂保持恒定,仅改变聚合物负载量。发现纳米颗粒的体外药物释放曲线遵循Higuchi平方根动力学,这意味着是扩散依赖性释放,正如预期的PLGA不溶性、非溶胀性所表现的那样。这表明形成的纳米颗粒本质上是基质型的,其中氟比洛芬均匀分散。针对不同响应,即药物释放(最大化)和粒径(最小化),生成了合适的多项式模型并使用方差分析进行统计验证。对这些模型进行数值求解并同时优化所需制剂。发现优化后的制剂的聚合物 - 药物比例为18.89:1,以4:1的非溶剂 - 溶剂比例制备,在8小时后释放最大化且粒径最小化。该方法避免了使用有机溶剂,从而提供了一种安全、可重复且快速的纳米颗粒生产方法。该研究探讨了水性聚合物药物递送系统的可行性和适用性,采用统计设计开发具有靶向潜力的临床有用纳米颗粒系统。